Equities Analysts Issue Forecasts for AxoGen Q3 Earnings

Key Points

• HC Wainwright analysts project AxoGen will report a Q3 2025 EPS of ($0.01) per share, with a full-year estimate at ($0.29) per share.
• AxoGen has received a Buy rating from four analysts, with an average target price of $25.75 for the stock.
• Institutional investors own 80.29% of AxoGen's shares, indicating strong support from the investment community.

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of AxoGen in a research note issued on Tuesday, September 30th. HC Wainwright analyst Y. Chen anticipates that the medical equipment provider will earn ($0.01) per share for the quarter. HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for AxoGen's Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.14 EPS.

Separately, Wall Street Zen upgraded AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, AxoGen presently has a consensus rating of "Buy" and an average target price of $25.75.

AxoGen Stock Performance

NASDAQ:AXGN opened at $17.88 on Friday. The company has a market cap of $822.66 million, a price-to-earnings ratio of -178.78 and a beta of 1.04. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59. AxoGen has a 52 week low of $9.22 and a 52 week high of $21.00. The company has a fifty day simple moving average of $15.59 and a two-hundred day simple moving average of $14.17.

Institutional Trading of AxoGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Squarepoint Ops LLC grew its position in shares of AxoGen by 259.2% in the 2nd quarter. Squarepoint Ops LLC now owns 483,563 shares of the medical equipment provider's stock valued at $5,247,000 after buying an additional 348,950 shares during the last quarter. State of Wyoming acquired a new position in AxoGen in the second quarter valued at $69,000. Tower Research Capital LLC TRC grew its holdings in shares of AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider's stock worth $55,000 after purchasing an additional 3,327 shares during the last quarter. Soleus Capital Management L.P. grew its holdings in shares of AxoGen by 0.9% during the second quarter. Soleus Capital Management L.P. now owns 1,459,395 shares of the medical equipment provider's stock worth $15,834,000 after purchasing an additional 13,278 shares during the last quarter. Finally, Wasatch Advisors LP increased its position in shares of AxoGen by 85.1% during the second quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock worth $15,557,000 after purchasing an additional 659,149 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.